Establishment of platform for screening insulin-like growth factor-1 receptor inhibitors and evaluation of novel inhibitors

Acta Pharmacologica Sinica

Volumn 32, Issue 7, 2011, Pages 930-938

  Tong, Lin Jiang ^a,b   Xie, Hua ^b   Peng, Ting ^b   Liu, Xiao Feng ^c   Xin, Xian Liang ^b   Huang, Xun ^b   Chen, Si Meng ^b   Liu, Hong Yan ^b   Li, Hong Lin ^c   Geng, Mei Yu ^b   Yin, Ming ^a   Ding, Jian ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

anticancer drug; apoptosis; cell proliferation; enzyme linked immunosorbent assay (ELISA); hematoxylin; HL 60 cell line; insulin like growth factor 1 receptor (IGF1R)

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; HEMATOXYLIN; I OME AG 538; NORDIHYDROGUAIARETIC ACID; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; BINDING AFFINITY; CANCER CELL; CANCER INHIBITION; CELL ASSAY; CELL PROLIFERATION; CELL STRAIN HL 60; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; MOLECULAR DOCKING; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SCREENING; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CATIONS, DIVALENT; CELL LINE; CELL PROLIFERATION; CLONING, MOLECULAR; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMATOXYLIN; HL-60 CELLS; HUMANS; MODELS, MOLECULAR; NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, IGF TYPE 1; SENSITIVITY AND SPECIFICITY;

EID: 79960068675     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.23     Document Type: Article

References (29)

1. Laviola L, Natalicchio A, Giorgino F. The IGF-I signaling pathway. Curr Pharm Des 2007; 13: 663-9. (Pubitemid 46510743)
2. Adams TE, Epa VC, Garrett TP, Ward CW. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 2000; 57: 1050-93. (Pubitemid 30598754)
3. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4: 505-18. (Pubitemid 38868620)
4. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007; 28: 20-47. (Pubitemid 46220849)
5. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007; 6: 1-12. (Pubitemid 46206663)
6. Dransfield DT, Cohen EH, Chang Q, Sparrow LG, Bentley JD, Dolezal O, et al. A human monoclonal antibody against insulin-like growth factor- II blocks the growth of human hepatocellular carcinoma cell lines in vitro and in vivo. Mol Cancer Ther 2010; 9: 1809-19.
7. Iwasa T, Okamoto I, Suzuki M, Hatashita E, Yamada Y, Fukuoka M, et al. Inhibition of insulin-like growth factor 1 receptor by CP-751871 radiosensitizes non-small cell lung cancer cells. Clin Cancer Res 2009; 15: 5117-25.
8. Blecha JE, Anderson MO, Chow JM, Guevarra CC, Pender C, Penaranda C, et al. Inhibition of IGF-1R and lipoxygenase by nordihydroguaiaretic acid (NDGA) analogs. Bioorg Med Chem Lett 2007; 17: 4026-9. (Pubitemid 46920923)
9. Ohshima-Hosoyama S, Hosoyama T, Nelon LD, Keller C. IGF-1 receptor inhibition by picropodophyllin in medulloblastoma. Biochem Biophys Res Commun 2010; 399: 727-32.
10. Gariboldi MB, Ravizza R, Monti E. The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells. Biochem Pharmacol 2010; 80: 455-62.
11. Chu CH, Huang CY, Lu MC, Lin JA, Tsai FJ, Tsai CH, et al. Enhancement of AG1024-induced H9c2 cardiomyoblast cell apoptosis via the interaction of IGF2R with Galpha proteins and its downstream PKA and PLC-beta modulators by IGF-II. Chin J Physiol 2009; 52: 31-7.
12. Haluska P, Carboni JM, TenEyck C, Attar RM, Hou X, Yu C, et al. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther 2008; 7: 2589-98.
13. Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG, et al. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res 2006; 66: 362-71. (Pubitemid 43166043)
14. Martins AS, Mackintosh C, Martin DH, Campos M, Hernandez T, Ordonez JL, et al. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 2006; 12: 3532-40.
15. Liu X, Xie H, Luo C, Tong L, Wang Y, Peng T, et al. Discovery and SAR of thiazolidine-2,4-dione analogues as insulin-like growth factor-1 receptor (IGF-1R) inhibitors via hierarchical virtual screening. J Med Chem 2010; 53: 2661-5.
16. Xie H, Qin YX, Zhou YL, Tong LJ, Lin LP, Geng MY, et al. GA3, a new gambogic acid derivative, exhibits potent antitumor activities in vitro via apoptosis-involved mechanisms. Acta Pharmacol Sin 2009; 30: 346-54.
17. Guo XN, Zhong L, Zhang XH, Zhao WM, Zhang XW, Lin LP, et al. Evaluation of active recombinant catalytic domain of human ErbB-tyrosine kinase, and suppression of activity by a naturally derived inhibitor, ZH-4B. Biochim Biophys Acta 2004; 1673: 186-93. (Pubitemid 38981772)
18. Blum G, Gazit A, Levitzki A. Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics. J Biol Chem 2003; 278: 40442-54. (Pubitemid 37280854)
19. Shelton JG, Steelman LS, White ER, McCubrey JA. Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells. Cell Cycle 2004; 3: 372-9. (Pubitemid 41359089)
20. Mulligan AM, OMalley FP, Ennis M, Fantus IG, Goodwin PJ. Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Res Treat 2007; 106: 39-47. (Pubitemid 47498088)
21. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002; 20: 42-51. (Pubitemid 34032594)
22. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001; 60: 91-106. (Pubitemid 32183103)
23. Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N, et al. Compensatory insulin receptor (IR) activation on inhibition of insulinlike growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther 2010; 9: 2652-64.
24. Kim KS. Multifunctional role of Fas-associated death domain protein in apoptosis. J Biochem Mol Biol 2002; 35: 1-6.
25. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-12. (Pubitemid 28406816)
26. Gossage L, Eisen T. Targeting multiple kinase pathways: a change in paradigm. Clin Cancer Res 2010; 16: 1973-8.
27. Iyer R, Fetterly G, Lugade A, Thanavala Y. Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother 2010; 11: 1943- 55.
28. Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007; 13: 1367-73. (Pubitemid 46450424)
29. Lin LG, Xie H, Li HL, Tong LJ, Tang CP, Ke CQ, et al. Naturally occurring homoisoflavonoids function as potent protein tyrosine kinase inhibitors by c-Src-based high-throughput screening. J Med Chem 2008; 51: 4419-29.